These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 30132686

  • 1. Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder.
    Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, Shahmoon S, Zisapel N, Gringras P.
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):699-710. PubMed ID: 30132686
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder.
    Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL.
    J Am Acad Child Adolesc Psychiatry; 2017 Nov; 56(11):948-957.e4. PubMed ID: 29096777
    [Abstract] [Full Text] [Related]

  • 3. Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder.
    Malow BA, Findling RL, Schroder CM, Maras A, Breddy J, Nir T, Zisapel N, Gringras P.
    J Am Acad Child Adolesc Psychiatry; 2021 Feb; 60(2):252-261.e3. PubMed ID: 31982581
    [Abstract] [Full Text] [Related]

  • 4. Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver's Quality of Life.
    Schroder CM, Malow BA, Maras A, Melmed RD, Findling RL, Breddy J, Nir T, Shahmoon S, Zisapel N, Gringras P.
    J Autism Dev Disord; 2019 Aug; 49(8):3218-3230. PubMed ID: 31079275
    [Abstract] [Full Text] [Related]

  • 5. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety.
    Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N.
    BMC Med; 2010 Aug 16; 8():51. PubMed ID: 20712869
    [Abstract] [Full Text] [Related]

  • 6. Pediatric prolonged-release melatonin for insomnia in children and adolescents with autism spectrum disorders.
    Schroder CM, Banaschewski T, Fuentes J, Hill CM, Hvolby A, Posserud MB, Bruni O.
    Expert Opin Pharmacother; 2021 Dec 16; 22(18):2445-2454. PubMed ID: 34314281
    [Abstract] [Full Text] [Related]

  • 7. [Therapeutic approaches for sleep and rhythms disorders in children with ASD].
    Schröder CM, Broquère MA, Claustrat B, Delorme R, Franco P, Lecendreux M, Tordjman S.
    Encephale; 2022 Jun 16; 48(3):294-303. PubMed ID: 35120753
    [Abstract] [Full Text] [Related]

  • 8. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response.
    Wade AG, Crawford G, Ford I, McConnachie A, Nir T, Laudon M, Zisapel N.
    Curr Med Res Opin; 2011 Jan 16; 27(1):87-98. PubMed ID: 21091391
    [Abstract] [Full Text] [Related]

  • 9. The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: a randomised, double-blind, placebo-controlled, parallel study (MENDS).
    Appleton RE, Jones AP, Gamble C, Williamson PR, Wiggs L, Montgomery P, Sutcliffe A, Barker C, Gringras P.
    Health Technol Assess; 2012 Jan 16; 16(40):i-239. PubMed ID: 23098680
    [Abstract] [Full Text] [Related]

  • 10. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder.
    Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H.
    Pediatrics; 2014 Oct 16; 134(4):e1095-103. PubMed ID: 25266438
    [Abstract] [Full Text] [Related]

  • 11. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial.
    Gringras P, Gamble C, Jones AP, Wiggs L, Williamson PR, Sutcliffe A, Montgomery P, Whitehouse WP, Choonara I, Allport T, Edmond A, Appleton R, MENDS Study Group.
    BMJ; 2012 Nov 05; 345():e6664. PubMed ID: 23129488
    [Abstract] [Full Text] [Related]

  • 12. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.
    Weiss MD, Surman C, Khullar A, He E, Cataldo M, Donnelly G.
    CNS Drugs; 2021 Jun 05; 35(6):667-679. PubMed ID: 34057707
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.
    Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N.
    Curr Med Res Opin; 2007 Oct 05; 23(10):2597-605. PubMed ID: 17875243
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.
    Krystal AD, Durrence HH, Scharf M, Jochelson P, Rogowski R, Ludington E, Roth T.
    Sleep; 2010 Nov 05; 33(11):1553-61. PubMed ID: 21102997
    [Abstract] [Full Text] [Related]

  • 15. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial.
    Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D.
    J Sleep Res; 2012 Dec 05; 21(6):700-9. PubMed ID: 22616853
    [Abstract] [Full Text] [Related]

  • 16. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
    Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Frydman-Marom A, Zisapel N.
    Clin Interv Aging; 2014 Dec 05; 9():947-61. PubMed ID: 24971004
    [Abstract] [Full Text] [Related]

  • 17. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia.
    Van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB.
    J Am Acad Child Adolesc Psychiatry; 2007 Feb 05; 46(2):233-41. PubMed ID: 17242627
    [Abstract] [Full Text] [Related]

  • 18. Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder.
    Zisapel N.
    Expert Rev Clin Pharmacol; 2022 Feb 05; 15(2):175-185. PubMed ID: 35285365
    [Abstract] [Full Text] [Related]

  • 19. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities.
    Wasdell MB, Jan JE, Bomben MM, Freeman RD, Rietveld WJ, Tai J, Hamilton D, Weiss MD.
    J Pineal Res; 2008 Jan 05; 44(1):57-64. PubMed ID: 18078449
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 05; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.